Home LiteratureArticle Details
PMID: 20533377 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Synapse loss in dementias.

Journal of neuroscience research ·Vol. 88 ·No. 10 ·2010-08-01 ·Pages 2083-90

Clare R, King VG, Wirenfeldt M, Vinters HV

Abstract

Synaptic transmission is essential for nervous system function, and its dysfunction is a known major contributing factor to Alzheimer's-type dementia. Antigen-specific immunochemical methods are able to characterize synapse loss in dementia through the quantification of various synaptic proteins involved in the synaptic cycle. These immunochemical methods applied to the study of Alzheimer's disease (AD) brain specimens have correlated synaptic loss with particularly toxic forms of amyloid-beta protein and have also established synapse loss as the best correlate of dementia severity. A significant but comparatively circumscribed amount of literature describes synaptic decline in other forms of dementia. Ischemic vascular dementia (IVD) is quite heterogeneous, and synapse loss in IVD seems to be variable among IVD subtypes, probably reflecting its variable neuropathologic correlates. Loss of synaptic protein has been identified in vascular dementia of the Binswanger type and Spatz-Lindenberg's disease. Here we demonstrate a significant loss of synaptophysin density within the temporal lobe of frontotemporal dementia (FTD) patients.

MeSH Terms
Animals Brain/physiopathology Dementia/physiopathology Humans Synapses/physiology
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Clare Ryan
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095-1732, USA.
King Victoria G
Wirenfeldt Martin
Vinters Harry V
References (56)
56 references, click to expand
  1. Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain.
    J Neurosci Res. 2006 Aug 15;84(3):632-6 PMID: 16721760
  2. Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging.
    J Neuropathol Exp Neurol. 1998 Oct;57(10):955-60 PMID: 9786245
  3. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction.
    J Alzheimers Dis. 2005 Apr;7(2):103-17; discussion 173-80 PMID: 15851848
  4. The synaptic vesicle cycle.
    Annu Rev Neurosci. 2004;27:509-47 PMID: 15217342
  5. Dementia with Lewy bodies versus pure Alzheimer disease: differences in cognition, neuropathology, cholinergic dysfunction, and synapse density.
    J Neuropathol Exp Neurol. 1997 May;56(5):499-508 PMID: 9143263
  6. SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release.
    Neuron. 1999 Dec;24(4):1003-16 PMID: 10624962
  7. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain.
    Neurology. 2004 Mar 23;62(6):925-31 PMID: 15037694
  8. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.
    Ann Neurol. 1991 Oct;30(4):572-80 PMID: 1789684
  9. Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease.
    Am J Pathol. 1992 Jun;140(6):1285-94 PMID: 1351366
  10. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.
    J Neurosci. 2000 Jun 1;20(11):4050-8 PMID: 10818140
  11. Frontal cortical synaptophysin in Lewy body diseases: relation to Alzheimer's disease and dementia.
    J Neurol Neurosurg Psychiatry. 1998 May;64(5):653-6 PMID: 9598683
  12. Synaptic loss in Alzheimer's disease and other dementias.
    Neurology. 1989 Mar;39(3):355-61 PMID: 2927643
  13. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study.
    JAMA. 1997 Mar 12;277(10):813-7 PMID: 9052711
  14. Vascular dementia in Spatz-Lindenberg's disease (SLD): cortical synaptophysin immunoreactivity as compared with dementia of Alzheimer type and non-demented controls.
    Acta Neuropathol. 1993;86(3):259-64 PMID: 8213084
  15. Synaptotagmin I: a major Ca2+ sensor for transmitter release at a central synapse.
    Cell. 1994 Nov 18;79(4):717-27 PMID: 7954835
  16. Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals.
    Neurobiol Aging. 2003 Dec;24(8):1047-62 PMID: 14643376
  17. Synaptobrevin binding to synaptophysin: a potential mechanism for controlling the exocytotic fusion machine.
    EMBO J. 1995 Jan 16;14(2):224-31 PMID: 7835333
  18. Synapse density related to cerebral blood flow and symptomatology in frontal lobe degeneration and Alzheimer's disease.
    Dement Geriatr Cogn Disord. 1999;10 Suppl 1:64-70 PMID: 10436344
  19. Cerebral microinfarcts associated with severe cerebral beta-amyloid angiopathy.
    Brain Pathol. 2010 Mar;20(2):459-67 PMID: 19725828
  20. Synaptotagmin I functions as a calcium regulator of release probability.
    Nature. 2001 Mar 1;410(6824):41-9 PMID: 11242035
  21. Cortical and subcortical patterns of synaptophysinlike immunoreactivity in Alzheimer's disease.
    Am J Pathol. 1991 Jan;138(1):235-46 PMID: 1899001
  22. Neuropathologic substrates of ischemic vascular dementia.
    J Neuropathol Exp Neurol. 2000 Nov;59(11):931-45 PMID: 11089571
  23. Quantitative assessment of cortical synaptic density in Alzheimer's disease.
    Neurobiol Aging. 1990 Jan-Feb;11(1):29-37 PMID: 2325814
  24. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards.
    Stroke. 2006 Sep;37(9):2220-41 PMID: 16917086
  25. Ca2+-dependent formation of a dynamin-synaptophysin complex: potential role in synaptic vesicle endocytosis.
    J Biol Chem. 2002 Mar 15;277(11):9010-5 PMID: 11779869
  26. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.
    J Neurosci. 2005 Oct 5;25(40):9096-101 PMID: 16207868
  27. The synaptic vesicle cycle: a cascade of protein-protein interactions.
    Nature. 1995 Jun 22;375(6533):645-53 PMID: 7791897
  28. Characterization of a synaptic antigen of interest in neuropsychiatric illness.
    Biol Psychiatry. 1992 Jan 15;31(2):147-58 PMID: 1737076
  29. Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias.
    Arch Neurol. 2001 Aug;58(8):1233-9 PMID: 11493163
  30. A protein assembly-disassembly pathway in vitro that may correspond to sequential steps of synaptic vesicle docking, activation, and fusion.
    Cell. 1993 Nov 5;75(3):409-18 PMID: 8221884
  31. Neurons and their dendrites in frontotemporal dementia.
    Dement Geriatr Cogn Disord. 1999;10 Suppl 1:55-60 PMID: 10436342
  32. Synaptic pathology and cell death in the cerebellum in Creutzfeldt-Jakob disease.
    Cerebellum. 2002 Jul;1(3):213-22 PMID: 12879983
  33. Neurons bearing neurofibrillary tangles are responsible for selected synaptic deficits in Alzheimer's disease.
    Neurobiol Aging. 1995 May-Jun;16(3):311-4 PMID: 7566340
  34. Vascular cognitive impairment.
    Nat Clin Pract Neurol. 2006 Oct;2(10):538-47 PMID: 16990827
  35. Synaptic degeneration is the primary neuropathological feature in prion disease: a preliminary study.
    Neuroreport. 1993 Jan;4(1):65-8 PMID: 8453038
  36. Cerebral amyloid angiopathy. A critical review.
    Stroke. 1987 Mar-Apr;18(2):311-24 PMID: 3551211
  37. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Am J Pathol. 1999 Sep;155(3):853-62 PMID: 10487842
  38. Neuritic pathology as a correlate of synaptic loss in dementia with lewy bodies.
    Am J Alzheimers Dis Other Demen. 2008 Feb-Mar;23(1):97-102 PMID: 18276962
  39. Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease.
    Arch Neurol. 1999 Dec;56(12):1458-61 PMID: 10593300
  40. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.
    Ann Neurol. 1990 May;27(5):457-64 PMID: 2360787
  41. Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.
    J Neural Transm (Vienna). 1996;103(5):603-18 PMID: 8811505
  42. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.
    J Neurol Sci. 1987 Apr;78(2):151-64 PMID: 3572454
  43. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3228-33 PMID: 10077666
  44. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations.
    Acta Neuropathol. 2009 Jan;117(1):15-8 PMID: 19015862
  45. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis?
    Bioessays. 2004 Apr;26(4):445-53 PMID: 15057942
  46. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.
    Neurology. 1996 Nov;47(5):1113-24 PMID: 8909416
  47. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease.
    Neuroscience. 1995 Jan;64(2):375-84 PMID: 7700527
  48. Synaptophysin immunoreactivity of the cortical neuropil in vascular dementia of Binswanger type compared with the dementia of Alzheimer type and nondemented controls.
    Dementia. 1994 Mar-Apr;5(2):79-87 PMID: 8038870
  49. Microvasculature in brain biopsy specimens from patients with Alzheimer's disease: an immunohistochemical and ultrastructural study.
    Ultrastruct Pathol. 1994 May-Jun;18(3):333-48 PMID: 8066824
  50. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration.
    Neurodegeneration. 1995 Jun;4(2):171-7 PMID: 7583681
  51. Ca2+-dependent interaction of the growth-associated protein GAP-43 with the synaptic core complex.
    Biochem J. 1997 Jul 15;325 ( Pt 2):455-63 PMID: 9230128
  52. Frontotemporal lobar degeneration: current concepts in the light of recent advances.
    Brain Pathol. 2007 Jan;17(1):104-14 PMID: 17493044
  53. Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy.
    Arch Neurol. 1999 Oct;56(10):1254-61 PMID: 10520942
  54. Amyloid angiopathy in Alzheimer's disease.
    Can J Neurol Sci. 1987 Nov;14(4):564-9 PMID: 3690426
  55. A novel enzyme-linked immunosorbent assay for determination of synaptophysin as compared with other quantification procedures.
    J Neuroimmunol. 1996 Jun;67(1):59-65 PMID: 8707931
  56. Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multi-infarct dementia.
    J Neural Transm. 1984;60(2):133-41 PMID: 6436437
Article Info
Journal
Journal of neuroscience research
Abbr.
J Neurosci Res
ISSN
1097-4547
DOI
10.1002/jnr.22392
Published
2010-08-01
Pages
2083-90
Language
English
Region
United States
NLM ID
7600111
PMCID
PMC3068914
Subset
IM
Grants
NIA NIH HHS · P50 AG016570-01 · United States
NIA NIH HHS · P50 AG16570 · United States
NIA NIH HHS · P50 AG016570 · United States
NIA NIH HHS · P01 AG012435 · United States
NIA NIH HHS · AG12435 · United States
NIA NIH HHS · P01 AG012435-05 · United States
External Links
PubMed source DOI: 10.1002/jnr.22392 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2